-

Cytovance Biologics Expands Services With In-House Formulation Development

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), announced the launch of its in-house formulation development services, significantly expanding its service offerings to biotech and pharmaceutical clients. This strategic enhancement reinforces the company’s position as a full-service partner for biologic drug developers.

Bringing formulation expertise in-house not only strengthens our technical capabilities but also reinforces Team Cytovance's mission to deliver smarter, faster, and more reliable development paths for our clients.

Share

“Adding formulation development capabilities is a major milestone for us,” said Axel Schleyer, Chief Commercial Officer of Cytovance Biologics. “It allows us to better serve our clients by accelerating development timelines and providing a truly integrated one-stop-shop approach, all while maintaining the highest standards of quality and regulatory compliance.”

This expansion reflects Cytovance’s continued investment in innovation and commitment to delivering comprehensive solutions for complex development challenges.

“Our formulation development workflow is grounded in Quality by Design (QbD) principles to deliver speed, safety, and data-driven precision from the outset,” added Fuad Haddadin, Head of R&D at Cytovance Biologics. “Bringing formulation expertise in-house not only strengthens our technical capabilities but also reinforces our mission to deliver smarter, faster, and more reliable development paths for our clients.”

The new services are now available to support existing and future client programs. Cytovance will showcase this and other offerings in Booth #606 at the BioProcess International conference in Boston this month.

About Cytovance:

Cytovance Biologics is an established large molecule CDMO that is large enough to support you at every stage and small enough to stay agile, providing your program with the care it deserves. For 20 years, Team Cytovance has offered flexibility and ingenuity across a full range of integrated services, supporting mammalian- and microbial-derived products on their journey from molecule to commercial manufacturing.

Follow us on LinkedIn: @Cytovance Biologics

Contacts

Media Inquiries: media@elementcg.co

Cytovance Biologics


Release Summary
Cytovance Biologics launches in-house formulation development, expanding end-to-end CDMO services for biotech and pharma customers.
Release Versions

Contacts

Media Inquiries: media@elementcg.co

Social Media Profiles
More News From Cytovance Biologics

Cytovance Biologics Launches In-House Cell Line Development with High-Yield Titers up to 10g/L

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics®, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its mammalian cell culture capabilities with the addition of cell line development services, strengthening its ability to provide a seamless path from DNA to IND submission for its customers. The launch of new cell line development services reflects Cytovance’s continued investment in innovati...

Cytovance Biologics Celebrates 20 Years of U.S.-Based Biomanufacturing Excellence in Oklahoma City

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance Biologics, a leading contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, is proud to celebrate its 20th anniversary in Oklahoma City. Since its founding in 2005, Cytovance has played a pivotal role in advancing biologic drug development and manufacturing, while helping establish Oklahoma as a growing hub for life sciences innovation. Cytovance marked the milestone with a well-attended celebration at Innovat...

Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs

OKLAHOMA CITY & TORRANCE, Calif.--(BUSINESS WIRE)--This new collaboration provides a scalable, integrated solution for developing and manufacturing complex peptide drugs efficiently....
Back to Newsroom